Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster

Andrew Dunn

Senior Biopharma Correspondent

Ahead of the busiest week for biopharma dealmaking at the annual JP Morgan Healthcare Conference, a new startup launched, believing its software will help prevent …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Ex­clu­sive: GV-backed start­up Pru­den­tia launch­es with $7M to help phar­ma make bet­ter deals, faster

Senior Biopharma Correspondent

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Exclusive: GV-backed startup Prudentia launches with $7M to help pharma make better deals, faster